Not medical advice. Talk to your provider before using any peptide. Full disclaimer
CJC-1295 (No DAC) vs Ipamorelin
Peptide Schedule Research TeamReviewed Apr 7, 202615 Citations
CJC-1295 without DAC (Mod GRF 1-29 in community reports) is a GHRH analog. Ipamorelin is a growth hormone secretagogue that works through a different receptor. Community protocols usually run them together. Neither is FDA-approved, and FDA found no study that gave CJC-1295 without DAC to people.
The community figured this one out before the researchers did. CJC-1295 without DAC, also called Mod GRF 1-29 (parent GRF(1-29) CAS 83930-13-6), is a 29-amino-acid GHRH analog modified at four positions to resist enzymatic breakdown. Its closest human data comes from Corpas et al. (1992, PMID 1379256), where GHRH(1-29) injected subcutaneously twice daily reversed the low GH and IGF-1 levels of old men. The mechanism is direct. Mod GRF 1-29 binds the GHRH receptor on pituitary somatotroph cells, triggering a cAMP-driven GH release that peaks around 15 to 30 minutes and clears within the hour. That short action window is the entire point. Unlike the DAC version (which circulates for days and produces tonic GH elevation), the no-DAC form preserves your natural pulsatile rhythm. Real-world use centers on the Mod GRF + Ipamorelin stack. Community consensus across hundreds of r/Peptides threads and practitioner networks puts the standard protocol at 100 mcg of each, co-injected subcutaneously once or twice daily on a fasted stomach before bed. Users consistently report improved sleep within the first two weeks, faster recovery by week three, and visible body composition changes by month two. Product quality is a known problem; Finnrick Analytics found purity as low as 68.75% across 244 samples from 47 companies. No FDA-approved form exists, and no Phase I, II, or III trial has been completed for Mod GRF 1-29 specifically.
View full guide →Zero cortisol increase at 200 times the effective GH dose. That single data point from Raun et al. (1998, PMID 9849822) explains why ipamorelin became the default starter peptide for growth hormone optimization. Ipamorelin (molecular weight ~711 Da) is a synthetic pentapeptide and selective GHS-R1a agonist. It binds the ghrelin receptor on pituitary somatotroph cells, producing a GH pulse within 15 to 30 minutes of subcutaneous injection. Gobburu and colleagues gave healthy men 15-minute IV infusions and modeled the result (1999, PMID 10496658). They measured a 2-hour half-life and one GH peak at about 40 minutes. The real-world use case is straightforward. Most users inject 100 to 300 mcg subcutaneously, one to three times daily on an empty stomach. Nearly everyone stacks it with CJC-1295 (no DAC), also called Mod GRF 1-29, to hit both GHS-R1a and GHRH receptor pathways simultaneously. That dual-pathway approach produces a GH pulse two to three times larger than either peptide alone. Bedtime dosing is the priority; the fasting window matters because insulin raises somatostatin, which fully blunts the GH response. Community evidence is strong. Hundreds of r/peptides threads (roughly 95,000 subscribers) consistently report improved sleep within one to two weeks, faster recovery by weeks three to four, and gradual body composition changes over six to twelve weeks. The scientific picture is less complete. The only published human RCT, a Phase 2 trial in 117 adults after bowel resection, missed its key endpoint versus placebo (Beck 2014, PMID 25331030). A second, 320-patient Phase 2 trial (NCT01280344) finished in 2014 without posted results or a paper. All efficacy data for anti-aging and body composition applications is community-derived. Preclinical work on bone mineral content (Svensson et al. 2000, PMID 10828840) and cachexia (2024 ferret model, PMID 39043357) looks promising but hasn't been replicated in humans.
View full guide →At a Glance
| Attribute | ||
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Safety Grade | B | B |
| Half-Life | ~30 min (estimated, never measured in humans) | ~2 hours |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 2 mg, 5 mg | 2 mg, 5 mg |
| Beginner Dose | 100 mcg Daily | 100 mcg Daily |
| Moderate Dose | 100 mcg 2x Daily | 200 mcg 2x Daily |
| Aggressive Dose | 200 mcg 2x Daily | 300 mcg 3x Daily |
| Dosing Source | Community | Community |
| Side Effects | The biggest safety concern with CJC-1295 (No DAC) is that zero completed clinical trials exist for this specific compound. Every side effect profile is extrapolated from analog studies and community experience. That context matters for everything below. Facial flushing is the most immediately noticeable effect. It typically hits within 5 to 15 minutes of injection, feels like a warm rush to the face and ears, and resolves within 30 to 60 minutes. This is a vasodilatory response from the GH pulse itself, not an allergic reaction. Community reports treat it as a sign the peptide is active. Reducing the dose lessens the intensity. Headache and dizziness occur in some users, usually during the first week. These tend to be transient and resolve as the body adjusts to regular GH pulses. Injection site redness and irritation are typical of any subcutaneous peptide; rotating sites prevents local tissue issues. Water retention is the side effect that gets the most community attention at higher dose frequencies. GH promotes sodium and water reabsorption. Mild puffiness around the hands and face is common, especially at twice-daily dosing. If retention becomes pronounced (visible edema, tight rings, swollen ankles), reduce frequency before reducing dose. Persistent edema warrants checking IGF-1 levels. Carpal tunnel symptoms (tingling, numbness in the hands, grip weakness) signal excessive GH-mediated fluid retention compressing the median nerve. This is a dose-dependent effect. Reduce dose immediately if it appears. If symptoms persist beyond one week at a lower dose, stop entirely and allow four or more weeks of recovery. GH release antagonizes insulin action. Anyone with diabetes, prediabetes, or insulin resistance should monitor fasting glucose carefully. Teichman et al. (2006, PMID 16352683) documented insulin sensitivity effects with the DAC form; the no-DAC form carries the same mechanistic risk at lower magnitude due to shorter exposure. GH promotes cell proliferation. Active cancer or a history of malignancy is a contraindication. Pregnancy and breastfeeding are absolute contraindications. Untreated hypothyroidism can blunt the GH response entirely and should be addressed before starting. Product quality adds an underappreciated risk layer. Finnrick Analytics tested 244 samples from 47 companies and found purity ranging from 68.75% to 99.95%. Underdosed or degraded product produces unpredictable responses; the no-DAC form (MW approximately 3,367 Da) is sometimes substituted with the DAC form (MW approximately 3,647 Da) in low-quality products. When to see a doctor: carpal tunnel symptoms that don't resolve with dose reduction, persistent unexplained edema, fasting glucose above 125 mg/dL, or any new numbness or paresthesia. | The most serious risk with ipamorelin is IGF-1 overshoot. Sustained supraphysiological IGF-1 levels carry a theoretical cancer promotion risk, particularly in anyone with active malignancy or a history of cancer. GH promotes cell proliferation. That's the mechanism behind its benefits and its biggest concern. If IGF-1 climbs above the age-adjusted upper normal range on two consecutive readings, the protocol should stop. Carpal tunnel symptoms (tingling or numbness in the hands) are the clearest signal that GH levels have gone too high. Community reports flag this primarily at the aggressive tier (300 mcg three times daily). This isn't a "push through it" side effect. Tingling means stop immediately, wait at least four weeks, and restart at a lower dose and frequency if appropriate. Water retention is common, especially at twice-daily or three-times-daily dosing. Mild puffiness around the face or ankles is the typical presentation. Reducing injection frequency (not dose) is the first adjustment. Transient headache within 30 to 60 minutes of injection is expected and relates directly to the acute GH pulse. It resolves within hours for most users. Cutting the dose by 25% usually handles persistent headache. Injection-site reactions (mild redness, irritation) are reported frequently in the first two weeks and tend to resolve with consistent site rotation. Abdomen is the preferred injection location. Occasional lightheadedness immediately post-injection is reported but typically mild. Published side effect data in humans is limited. Only one human RCT has been published (Phase 2, 117 adults after bowel resection, PMID 25331030). It used intravenous dosing and tracked adverse events, but its endpoints were GI recovery, not the subcutaneous anti-aging use case. A second Phase 2 trial in 320 bowel-resection patients (NCT01280344) finished in 2014 and never posted results. Community side-effect reporting across hundreds of threads is remarkably consistent, which provides reasonable confidence in the profile above, but formal incidence rates don't exist for the off-label application. GH release antagonizes insulin action. Fasting glucose should be monitored at baseline, week six, and week twelve. Anyone with uncontrolled diabetes or severe insulin resistance should not use ipamorelin. A fasting glucose above 126 mg/dL means discontinuation. Pregnancy and breastfeeding are contraindicated due to insufficient safety data. GH supplementation can also unmask subclinical hypothyroidism by accelerating T4-to-T3 conversion; thyroid monitoring (TSH, fT3) is recommended at baseline. When to see a doctor: persistent hand tingling or numbness, significant edema, fasting glucose above 126 mg/dL, any visual changes, or symptoms of intracranial hypertension. |
Key Differences
They act on different receptors. CJC-1295 is a 29-amino acid GHRH analog, so it acts on the GHRH receptor (FDA CJC-1295 briefing). Ipamorelin is a pentapeptide [1] that activates ghrelin receptors on the pituitary and in the hypothalamus (FDA ipamorelin briefing).
The CJC-1295 on this page has no DAC. It is GHRH(1-29) with amino acid swaps at positions 2, 8, 15 and 27 (FDA CJC-1295 briefing). CJC-1295 with DAC is a longer-acting relative. One injection kept GH up for 6 days or more in healthy adults, and its half-life was 5.8 to 8.1 days [4].
Ipamorelin stays in the blood longer. After IV infusions in healthy men, its terminal half-life was 2 hours, and GH peaked once at about 40 minutes [2]. No study has measured CJC-1295 without DAC; the 30 minutes in the table is a community estimate. A close analog, D-Ala2 GHRH(1-29), had a disappearance half-time of 6.7 minutes during IV infusion [3].
Human evidence is thin for both and thinner for CJC-1295. FDA found no study in which CJC-1295 without DAC was given to people (FDA CJC-1295 briefing). Ipamorelin has a dosing study in healthy men and a published phase 2 trial in 117 patients after bowel surgery [5]. A second phase 2 trial enrolled 320 people and never posted results (NCT01280344).
That published ipamorelin trial missed its goal. Given by IV after bowel resection, ipamorelin didn't shorten the time to a first tolerated solid meal. It took 25.3 hours vs 32.6 on placebo (p = 0.15)[5]. Its use for GH, sleep and body composition rests on community reports.
Ipamorelin's selectivity comes from animal data. In swine, it released GH without the ACTH and cortisol rise that two older GHRPs caused [1]. That held at more than 200 times the dose giving half its peak GH release, and prolactin did not change. Community reports add that it causes less hunger than older GHRPs.
Side effect data come from a different molecule. In the CJC-1295 with DAC studies, about 70% had injection-site reactions. Some had flushing, headache, low blood pressure or a faster heart rate (FDA CJC-1295 briefing). FDA found no safety data at all for the version without DAC.
Ipamorelin's safety data come from hospital patients given IV doses after bowel surgery. Two people on ipamorelin died after surgical complications, and FDA said it is unclear whether ipamorelin played a role. Low potassium (12.5% vs 3.4%) and high blood sugar at discharge (14.3% vs 8.6%) were more common on ipamorelin (FDA ipamorelin briefing).
Community dosing, not trial dosing: CJC-1295 without DAC runs 100 mcg once or twice a day, up to 200 mcg. Ipamorelin runs 100 to 300 mcg per injection, one to three times a day. Community reports favor injecting on an empty stomach, often at bedtime.
FDA says no approved drug contains either peptide (FDA briefings). Its compounding advisory committee voted against adding both to the 503A bulks list. On December 4, 2024, CJC-1295 drew 0 yes and 13 no as the free base, and 1 yes and 12 no as acetate (FDA minutes).
Ipamorelin drew 0 yes, 12 no and 1 abstention for each form on October 29, 2024 (FDA minutes). FDA calls these votes non-binding, and 21 CFR 216.23 lists neither peptide. FDA's category 2 page lists CJC-1295 and ipamorelin acetate as nominated but withdrawn, and ipamorelin acetate stays in 503B category 2 (FDA category 2 page).
WADA prohibits both at all times as growth hormone releasing factors, under S2.2.4 (WADA 2026 list).
When to Choose CJC-1295 (No DAC)
You plan to stack with a GHRP and want the GHRH half (the usual community protocol)
A short-acting GHRH fits a daily pulse routine (community reports; its half-life was never measured)
Sleep depth is the main goal (the most cited community benefit; no trial has tested it)
Verdict
Ipamorelin has more human data, though still thin: a dosing study in healthy men and one published phase 2 trial that missed its goal. FDA found no human study of CJC-1295 without DAC. Its longer-acting relative with DAC raised GH for days in healthy adults [4]. Community reports treat the two as a pair and run them together. Used alone, ipamorelin is the more common starting point in community reports.
Research peptides with both sides of the evidence.
Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.
Can You Stack CJC-1295 (No DAC) + Ipamorelin?
CJC-1295 + ipamorelin is the most common GH peptide stack in community reports, and it has its own page on Peptide Schedule. Ipamorelin starts a GH pulse through the ghrelin receptor while CJC-1295 acts on the GHRH receptor, so the two don't compete. Community protocols co-inject 100 to 300 mcg of each, once or twice a day, usually at bedtime. FDA noted that ipamorelin is marketed in combination with CJC-1295 (FDA ipamorelin briefing). No trial has tested the pair; a ClinicalTrials.gov search on October 15, 2026, found none registered.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Related Guides & Stacks
Peptide Schedule Research TeamReviewed Apr 8, 202615 Citations
References
- [1]Ipamorelin, the first selective growth hormone secretagogue (Raun et al., Eur J Endocrinol 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Gobburu et al., Pharm Res 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]D-Ala2 GHRH(1-29)-NH2 half-life and clearance in normal men (Soule et al., J Clin Endocrinol Metab 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]CJC-1295 with DAC in healthy adults: GH and IGF-I raised for days after one injection (Teichman et al., J Clin Endocrinol Metab 2006) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Ipamorelin for postoperative ileus after bowel resection, phase 2 proof-of-concept trial (Beck et al., Int J Colorectal Dis 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- FDA briefing document: CJC-1295-related bulk drug substances, Pharmacy Compounding Advisory Committee, December 4, 2024 (opens in a new tab)FDA Label
- FDA briefing document: ipamorelin, Pharmacy Compounding Advisory Committee, October 29, 2024 (opens in a new tab)FDA Label
- ClinicalTrials.gov NCT01280344: ipamorelin vs placebo for recovery of gastrointestinal function after bowel resection, phase 2, 320 enrolled (completed 2014, no results posted) (opens in a new tab)Clinical Trial
- ClinicalTrials.gov NCT00267527: CJC-1295 vs placebo in HIV-associated visceral obesity, phase 2 (terminated 2006, no results) (opens in a new tab)Clinical Trial
- FDA final summary minutes, Pharmacy Compounding Advisory Committee, December 4, 2024: CJC-1295 free base 0-13-0, acetate 1-12-0, each DAC form 0-13-0 (opens in a new tab)FDA Label
- FDA final summary minutes, Pharmacy Compounding Advisory Committee, October 29, 2024: ipamorelin free base and acetate each 0 yes, 12 no, 1 abstain (opens in a new tab)FDA Label
- FDA: October 29, 2024 Pharmacy Compounding Advisory Committee meeting page ("Advisory committees make non-binding recommendations to the FDA") (opens in a new tab)FDA Label
- FDA: bulk drug substances in compounding that may present significant safety risks, category 2 and nominated-but-withdrawn lists (current as of April 22, 2026) (opens in a new tab)FDA Label
- 21 CFR 216.23: bulk drug substances that can be used in 503A compounding (eCFR, current through October 13, 2026; last amended 2019) (opens in a new tab)FDA Label
- World Anti-Doping Agency, 2026 Prohibited List: BPC-157 under S0; thymosin beta-4 and TB-500 under S2.3; CJC-1295, sermorelin and ipamorelin under S2.2.4; prohibited at all times (opens in a new tab)Review